دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Leaders of change: does it take a patient to put patients first?
doi : 10.1016/S1470-2045(21)00725-7
Volume 23, Issue 1, January 2022, Page 1
Targeting BRAF-mutant glioma: reflections on the ROAR trial
Katherine BPetersa
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study
MariaReigabMarcoSanduzzi-Zamparelliab
CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?
Noa GHoltzmanaNirali NShahb
Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART
Lizza E LHendriksaDirk K MDe Ruysschera
KRASG12C inhibition in colorectal cancer
PerPfeifferaCamillaQvortrupb
All eyes on the EuroNet-PHL-C1 trial for paediatric classical Hodgkin lymphoma
Monika LMetzgera
Risk-based lung cancer screening eligibility criteria: towards implementation
Kevinten Haafa
Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk
FelixStickelaJochenHampeb
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
Muhammad BilalAbidab
Prioritising access to cancer drugs
Mitchell JElliottaEitanAmiraSallie-AnnePearsonbcMichael BBartondBrooke EWilsonad
Prioritising access to cancer drugs
Corinna Victoria MPuyataMichelle Ann BEalaaEdward ChristopherDeebOurlad Alzeus GTantengcoaAnna Rominia D PCruzaEdgar AFaylonacMaria Julieta VGermardDennis LSacdalane
Radiographic progression-free survival in the ACIS trial for prostate cancer
ShaiGilboaaDavidBomzeaGalMarkelabTomerMeirsonb
Radiographic progression-free survival in the ACIS trial for prostate cancer
Ian FTannockaChristopher MBoothbBishalGyawalibAnthony MJoshuac
Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply
FredSaadaPeterDe PorrebSabineBrookman-MaycdJinhuiLieSharon AMcCarthyfDana ERathkopfg
Assessment of tumour-agnostic therapies in basket trials
SanjayPopataSreeram VRamagopalanbJoshuaRaybStéphaneRozecVivekSubbiahd
Assessment of tumour-agnostic therapies in basket trials
OlivierCollignonaMartinPoschbAnjaSchielc
Alternative analysis of the data from a HPV vaccine study in India
PeterSasienia
Alternative analysis of the data from a HPV vaccine study in India – Authors' reply
ParthaBasuaRichardMuwongea
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer
AlessandroRizzoaAngela DaliaRicciaGiovanniBrandia
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer – Author's reply
ChanghoonYooaNIFTY trial investigators
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
PierpaoloCorrealeabFrancescaPentimallicValerioNardonedAntonioGiordanobeLucianoMuttibf
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply
Dean AFennellaGarethGriffithsbChristianOttensmeiercGerard GHannadeSarahDansonfPeterSzlosarekgMavisNyeh
Build Back Better Act could affect US community-based oncology practices
ManjulikaDas
COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths
EmmaWilkinson
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA
StephanieParker
WHO and St Jude Children's Research Hospital announce childhood cancer medicines initiative
Talha KhanBurki
Shamim Nabuuma Kaliisa: survivor takes on cancer with AI
MunyaradziMakoni
Should brachytherapy be added to external beam radiotherapy for prostate cancer?
AlfonsoGomez-IturriagaaMiraKeyesbJaradMartincDaniel ESprattd
ICGC-ARGO precision medicine: familial matters in pancreatic cancer
MicheleMilellaaClaudioLuchinibRita TLawlorbAmber LJohnscRaffaellaCasolinoadTakayukiYoshinoeAndrew VBiankindfg
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
ProfPatrick YWenMDaAlexanderSteinMDbProfMartinvan den BentMDcJacquesDe GreveMDdAntjeWickMDeFilip Y F Lde VosMDfProfNikolasvon BubnoffMDghMyra Evan LindeMDiAlbertLaiMDjGerald WPragerMDkProfMarioCamponeMDlAngelicaFasoloMDmJose ALopez-MartinMDnTae MinKimMDoWarren PMasonMDpProfRalf-DieterHofheinzMDqProfJean-YvesBlayMDrProfDaniel CChoMDs…VivekSubbiahMDy
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad ZUsmaniMDaHangQuachMDbMaria-VictoriaMateosMDcProfOlaLandgrenMDdXavierLeleuMDeDavidSiegelMDfProfKatjaWeiselMDgMariaGavriatopoulouMDhAlbertOriolMDiNeilRabinMBBSjAjayNookaMDkMingQiMDlMeralBeksacMDmAndrzejJakubowiakMDnBifengDingMSoAnitaZahlten-KumeliPhDoAkeemYusufPhDoProfMeletiosDimopoulosMDp
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
ThomasYauMDaJoong-WonParkMDbProfRichard SFinnMDcProfAnn-LiiChengMDdProfPhilippeMathurinMDeJulienEdelineMDfProfMasatoshiKudoMDgJames JHardingMDhiProfPhilippeMerleMDjProfOlivierRosmorducMDkProfLucjanWyrwiczMDlProfEckartSchottMDmSu PinChooMDnProfRobin KateKelleyMDoWolfgangSieghartMDpProfEricAssenatMDqProfRenataZauchaMDrProfJunjiFuruseMDs…ProfBrunoSangroMDw
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron AJacobsonMDaJulio CChavezMDbAlison RSehgalMDcBasem MWilliamMDdJavierMunozMDeProfGillesSallesMDfPashna NMunshiMDgCarlaCasuloMDhProfDavid GMaloneyMDiSvende VosMDjRanReshefMDkLori ALeslieMDlProfIbrahimYakoub-AghaMDmOlalekan OOluwoleMDnProfHenry Chi HangFungMDoJosephRosenblattMDpJohn MRossiMSqLovelyGoyalPhDq…ProfSattva SNeelapuMDr
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
CecileLe PechouxMDaNicolasPourelMDdProfFabriceBarlesibeDelphineLerougeMDfDelphineAntoniMDgBrunoLamezecMDhProfUrsulaNestleMDijPierreBoisselierMDkEricDansinMDlAmauryPaumierMDmKarinePeignauxMDnFrançoisThillaysMDoProfGerardZalcmanMDpqJeannickMadelaineMDpEricPichonMDrAnneLarrouyMDsArmelleLavoleMDtDelphineArgo-LeignelMDu…AurelieBardetMSccac
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
ProfMarwan GFakihMDa†ProfScottKopetzMDb†ProfYasutoshiKubokiMDcProfTae WonKimMDdProfPamela NMunsterMDeProfJohn CKraussMDfProfGerald SFalchookMDgProfSae-WonHanMDhProfVolkerHeinemannMDiProfKeiMuroMDjProfJohn HStricklerMDkProfDavid SHongMDbCrystal SDenlingerMDlProfGustavoGirottoMDmProfMyung-AhLeeMDnHabyHenaryMDoQuiTranPhDoJoseph KParkMDo…ProfTimothy JPriceDHthScq
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
ProfChristineMauz-KörholzMDab*ProfJudithLandman-ParkerMDd*ProfWalentynaBalwierzMDe*ProfRoland AAmmannMDfProfRichard AAndersonMDgAndischeAttarbaschiMDhJörg MBarteltMDjAukeBeishuizenMDkSabahBoudjemaaMDlMichaelaCepelovaMDmProfAlexanderClaviezMDnStephenDawMDoProfKarinDieckmannMDqProfAnaFernández-TeijeiroMDrAlexanderFossÃ¥MDsProfStefanGattenlöhnerMDtThomasGeorgiMDuLisa LHjalgrimMDw…ProfWilliam HamishWallaceMDaeâ€
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study
ProfMartin CTammemägiPhDaMamtaRuparelMBBSbProfAlainTremblayMDCMcRenelleMyersFRCPCefJohnMayoFRCPCgJohnYeeFRCPChSukhinderAtkar-KhattraBSceRenYuanFRCPCjkSonyaCressmanPhDlJohnEnglishFRCPCiEricBedardFRCPCmPaulMacEachernFRCPCdPaulBurrowesFRCPCnSamantha LQuaifePhDoHenryMarshallMBBSpProfIanYangMBBSpRayleenBowmanMBBSpLindaPassmoreBNp…ProfStephenLamFRCPCe*
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
ChristinaYauPhDa†MarieOsdoitMDad*Mariekevan der NoordaaMDaSonalShadBSaJaneWeiBSaDianede CrozeMDeAnne-SophieHamyMDfMarickLaéMDegProfFabienReyalMDdProfGabe SSonkeMDhTessa GSteenbruggenMDhMaartjevan SeijenMDiProfJelleWesselingMDiProfMiguelMartÃnMDjMariadel Monte-MillánBScjSaraLópez-TarruellaMDj
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
EricTrépoPhDabc*StefanoCarusoPhDa*JieYangPhDad*SandrineImbeaudPhDaGabrielleCouchyPhDaQuentinBayardPhDaEricLetouzéPhDaProfNathalieGanne-CarriéPhDaeProfChristopheMorenoPhDbcProfAbderrahimOussalahPhDfghProfCyrilleFérayPhDiProfJean FrédéricBlancPhDjkProfBrunoClémentPhDlProfPatrickHillonPhDmnoProfJérômeBoursierPhDpqProfValérieParadisPhDrProfJulienCalderaroPhDstVivianeGnemmiPhDu…ProfJessicaZucman-RossiPhDaab
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
VivekNaranbhaiDPhilabc*MathiasViardPhDd*MichaelDeanPhDeStefanGrohaPhDbDavid ABraunPhDbChrisLabakiMDbSachet AShuklaPhDbYukoYukiDMDdParantuShahPhDfKevinChinMDgMeganWind-RotoloPhDhXinmeng JasmineMuPhDiPaul BRobbinsPhDjAlexanderGusevPhDbProfToni KChoueiriMDbJames LGulleyMDkMaryCarringtonPhDdl
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer
IcroMeattiniMDabCarlottaBecheriniMDabProfLiesbethBoersmaMDcOritKaidar-PersonMDcdGustavo NaderMartaMDefAngelMonteroMDgProfBirgitte VrouOffersenMDhMarianne CAznarPhDijProfClausBelkaMDkProfAdrian MurrayBruntFRCRlmSamanthaDicuonzoMDnPierfrancescoFrancoMDopMechthildKrauseMDqrstuMaireadMacKenzieMDvTanjaMarinkoMDwxLiviaMarrazzoMScyIvicaRatosaMDwxAstridScholtenMDz…ProfCharlotte EColesFRCRad*
Clinical advances in PET–MRI for breast cancer
Amy MFowlerMDabcRoberta MStrigelMDabc
The tumours and the three bumps
ProfValérieBoussonMDaJean-PierreGuichardMDbProfSébastienFroelichMDbProfPhilippeOrcelMDc
